Radioactive drug plus surgery: new hope for neuroendocrine cancer?
NCT ID NCT04609592
First seen Sep 30, 2025 · Last updated Jun 11, 2026 · Updated 35 times
Summary
This early-phase study tests whether giving a radioactive drug (Lutathera) before and after surgery is safe and feasible for people with advanced neuroendocrine tumors that have spread to the liver or lymph nodes. About 10 participants will receive two cycles of the drug, then undergo surgery to remove as much tumor as possible. The goal is to see if this combined approach can improve outcomes without causing serious complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford Cancer Institute Palo Alto
RECRUITINGStanford, California, 95304, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.